Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03602079 · ClinicalTrials.gov registry record · Phase 1
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
A Phase 1 study, sponsored by Klus Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03602079 is a Phase 1 study that has completed, run by Klus Pharma. The registered enrollment target is 49 participants.
The verdict
NCT03602079, a Phase 1 study, has completed, sponsored by Klus Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.
Interventions
- DRUG A166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03602079
The ClinicalTrials.gov registry entry for NCT03602079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Klus Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A166 is the first listed.
NCT03602079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03602079 about?
NCT03602079 is a clinical study titled "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene". Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard th...
What is the current status of trial NCT03602079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-07-16. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT03602079?
The interventions under investigation include: A166 (DRUG).
Who is sponsoring clinical trial NCT03602079?
This trial is sponsored by Klus Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.